Document Details

(491 K)

ANITBODY RESPONSE IN PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA ( CANCER 37:2177-2182, 1976 ) ( PARTIAL DOCUMENT )

JOSEPH, M J [MARYLAND DEPARTMENT OF HEALTH]; LICHTENFELD, J L [MARYLAND DEPARTMENT OF HEALTH]; MARDINEY, M R [MARYLAND DEPARTMENT OF HEALTH]; SCHIFFER, C A [MARYLAND DEPARTMENT OF HEALTH]; WIERNIK, P H [MARYLAND DEPARTMENT OF HEALTH]

HREX

Location - DOE/NNSA NUCLEAR TESTING ARCHIVE Address - P.O. Box 98521 City - Las Vegas State - NV Zip - 89193-8521 Phone - (702)794-5106 Fax - (702)862-4240 Email - NTA@NV.DOE.GOV

JOURNAL ARTICLE

1976 Dec 31

Never classified

0006

NV0702313

1994 Aug 27

2017 Dec 21

LYMPHOCYTOTOXIC (LCT) AND ANTI-RED BLOOD CELL (ABO) ANTIBODIES WERE MEASURED SERIALLY IN ADULT PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA (ANLL) RECEIVING INDUCTION CHEMOTHERAPY. THE ANTIGENIC STIMULUS WAS PROVIDED BY MULTIPLE PLATELET TRANSFUSIONS, MANY OF WHICH WERE ABO INCOMPATIBLE. COMPARISON OF PRE-THERAPY TITERS 4-6 WEEKS INTO THERAPY SHOWS THAT 50 PERCENT OF PATIENTS (19/38) OF PATIENTS BECAME LCT POSITIVE (CYTOTOXICITY AGAINST > 10 PERCENT OF PANEL OF CELLS) AND 54 PERCENT (19/35) HAD INCREASES IN ABO TITERS (> 2 TUBE DILUTION). A TOTAL OF 66 PERCENT OF PATIENTS HAD SIGNIFICANT RISES IN AT LEAST ONE ANTIBODY. ABO AND LCT TITERS TENDED TO VARY IN PARALLEL ALTHOUGH EXCEPTIONS WERE NOTED. THE DEVELOPMENT OF ANTIBODY COULD NOT BE CORRELATED WITH (1) PRE OR POST-TREATMENT IMMUNOGLOBULIN LEVELS, (2) REMISSION RATE OR DURATION, (3) TYPE OF THERAPY, (4) NUMBER OF PLATELET TRANSFUSIONS, (5) TIME RELATIONSHIP BETWEEN THE ANTIGENIC STIMULUS AND THE INITIATION OF CYTOTOXIC THERAPY, AND, (6) SKIN TEST REACTIVITY. ANTIBODY RESPONDERS TENDED TO HAVE HIGHER PRETREATMENT LYMPHOCYTE COUNTS. THE ABILITY TO DEVELOP A SECONDARY ANTIBODY RESPONSE DOES NOT APPEAR TO BE A MAJOR PROGNOSTIC FACTOR IN ANLL.